120418-62-4

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Chlorophenyl)pyrrolidine is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential therapeutic effects. Its unique chemical structure allows for the development of new drugs and medications with improved efficacy and safety profiles.
Used in Research Applications:
In the field of research, 3-(4-Chlorophenyl)pyrrolidine serves as a valuable tool for studying the structure-activity relationships of pyrrolidine-based compounds. It aids in understanding the molecular mechanisms underlying their pharmacological actions and helps in the design of more effective and targeted therapeutic agents.
It is important to handle 3-(4-Chlorophenyl)pyrrolidine with care and follow proper safety protocols when working with it in a laboratory setting to ensure the safety of researchers and the integrity of the experiments.

InChI:InChI=1/C10H12ClN/c11-10-3-1-8(2-4-10)9-5-6-12-7-9/h1-4,9,12H,5-7H2

Upstream product

• 22518-27-0 4-(4-chlorophenyl)pyrrolidin-2-one 
• 231622-37-0 1-benzyl-3-(4-chloro-phenyl)-pyrrolidine 
• 108005-47-6 2-(4-chlorophenyl)succinonitrile 
• 1134-47-0 4-amino-3-(4-chlorophenyl)butanoic acid 
• 14774-78-8 4-chlorophenyl lithium 
• 1628-19-9 3-(4-chlorophenyl)-pyrrolidine-2,5-dione 

Downstream Products

• 877614-86-3 tert-butyl 3-(4-chlorophenyl)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3

Fibroblast growth factor receptors (FGFR) 2 and 3 have been established as drivers of numerous types of cancer with multiple drugs approved or entering late stage clinical trials. A limitation of current inhibitors is vulnerability to gatekeeper resistance mutations. Using a combination of targeted high-throughput screening and structure-based drug design, we have developed a series of aminopyrazole based FGFR inhibitors that covalently target a cysteine residue on the P-loop of the kinase. The inhibitors show excellent activity against the wild-type and gatekeeper mutant versions of the enzymes. Further optimization using SAR analysis and structure-based drug design led to analogues with improved potency and drug metabolism and pharmacokinetics properties.

N-Substituted-3-arylpyrrolidines: Potent and Selective Ligands at Serotonin 1A Receptor

3-Arylpyrrolidines are synthesized through the coupling of N-benzyl-3-(methanesulfonyloxy)pyrrolidine with diarylcuprates. Pharmacological evaluation of a series of N-substituted-3-arylpyrrolidines toward several neurotransmitter receptors indicated that some of them are good ligands for serotonin 1A receptor. Particularly, N-pyrrolidines were found to be potent and selective ligands. A preliminary biological evaluation for several selected compounds indicated that they are potentially effective antianxiety and antidepressant agents.

Metabolism of 3-(p-chlorophenyl)pyrrolidine. Structural effects in conversion of a prototype γ-aminobutyric acid prodrug to lactam and γ-aminobutyric acid type metabolites

By use of rat liver or brain homogenate supernatants containing microsomes and/or mitochondria, it was found that the prototype GABAergic prodrug [3-(p-chlorophenyl)pyrrolidine (1) underwent a series of α-oxidation transformations to a pair of amino acid metabolites and a pair of lactam metabolites [4-amino-3-(p-chlorophenyl)butanoic acid, baclofen (5); 4-amino-2-(p-chlorophenyl)butanoic acid (10); 4-(chlorophenyl)pyrrolidin-2-one (6); and 3-(p-chlorophenyl)pyrrolidine-2-one (11)]. With the liver homogenates, the formation of the lactam metabolites was approximately 2 orders of magnitude greater than that of the amino acid metabolites, while with the brain homogenates, the amino acid and lactam pathways were of similar magnitude. For either tissue, for both the lactam and the amino acid series, attack at the less sterically hindered 5-position of the pyrrolidine ring was greater than the attack at the 2-position (5>10 and 6>11) with the exception of the liver homogenate mitochondrial fraction (611). The parenteral administration of the prodrug 1 was found to give detectable brain levels of 5 as well as activity in an isoniazid-induced (GABA-inhibited) convulsion model.